Helena Yu, MD, discusses research updates from REZILIENT1 that were presented at ASCO 2025.
EGFR+ Non-Small Cell Lung Cancer
Advertisement
The study compared treatment with neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone.
Jennifer Carlisle, MD, discusses amivantamab, and the multidimensional impact of toxicity management at ASCO 2025.
Dr. Spira shares key data from cohort C of CHRYSALIS-2 that was presented at the European Lung Cancer Congress 2025.
Dr. Liu discusses key data and updates in EGFR-positive NSCLC from the European Lung Cancer Congress.
Nicolas Girard, MD, PhD, discusses data on subcutaneous amivantamab in patients with advanced NSCLC.
Suresh S. Ramalingam, MD, FACP, FASCO, presented the data during a proffered paper session at ELCC 2025.
The study is evaluating regimens to prevent dermatologic adverse events in patients receiving amivantamab plus lazertinib.
Myung-Ju Ahn, MD, PhD, presented data from the study during the first proffered paper session of ELCC 2025.
Xiuning Le, MD, PhD, presented results from the ORCHARD trial at ELCC 2025.
Amivantamab plus lazertinib showed a statistically significant improvement in OS compared with osimertinib.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.